When good cholesterol turns bad: The evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein

Current Diabetes Reports

Volumn 8, Issue 3, 2008, Pages 165-167

  Oram, John F ^a   Heinecke, Jay W ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; TORCETRAPIB; ABC TRANSPORTER; ABC TRANSPORTER A1; CHOLESTEROL ESTER TRANSFER PROTEIN;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HEART PROTECTION; HUMAN; HYPERTENSION; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NONHUMAN; NOTE; PATHOPHYSIOLOGY; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; ANIMAL; ARTICLE; ATHEROSCLEROSIS; BLOOD; DRUG ANTAGONISM; METABOLISM; RABBIT; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; LIPOPROTEINS, HDL; RABBITS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 52649182197     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0028-8     Document Type: Note

References (11)

1. Duffy D, Rader DJ: Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006, 113:1140-1150.
2. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
3. Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
4. Barter PJ, Brewer HB Jr, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160-167.
5. Okamoto H, Yonemori F, Wakitani K, et al.: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406:203-207.
6. Yvan-Charvet L, Matsuura F, Wang N, et al.: Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007, 27:1132-1138.
7. Oram JF, Heinecke JW: ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005, 85:1343-1372.
8. Chait A, Han CY, Orarn JF, Heinecke JW: Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005, 46:389-403.
9. Shao B, Oda MN, Orarn JF, Heinecke JW: Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006, 21:322-328.
10. Bergt C, Pennathur S, Fu X, et al.: The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004, 101:13032-13037.
11. Vaisar T, Pennathur S, Green PS, et al.: Shotgun proteomics implicates protease inhibition and complement acitivation in the anti-inflammatory properties of HDL. J Clin Invest 2007, 117:746-756.